QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N

Stock News

05/27

QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as "Roche") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).

QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.

On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1162349960"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162349960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162349960?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162349960","market":"nz","top_or_hot":-1,"title":"QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N","media":"Stock News","content":"<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1162349960","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162349960","pubTimestamp":1779886961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"QYUNS-B在QX031N I期试验中首次患者给药后收到罗氏的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).\nQX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.\nOn October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}